ADICON Holdings Limited, advised by Kirkland & Ellis, is set to acquire Crown Bioscience from JSR Life Sciences for an enterprise value of $204 million, enhancing its clinical laboratory services and capabilities in precision medicine.
Target Information
ADICON Holdings Limited, publicly traded on the Hong Kong Stock Exchange under the ticker HKEX: 9860, specializes in providing independent clinical laboratory services. The company has established itself as a key player in the healthcare sector, focusing on delivering accurate and reliable diagnostic testing services to hospitals, clinics, and other healthcare providers.
With a comprehensive portfolio of laboratory offerings, ADICON aims to enhance patient care through improved diagnostic efficiency. This acquisition marks a significant step in expanding its capabilities and services within the clinical laboratory field.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in China
The clinical laboratory industry in China has seen substantial growth driven by increasing healthcare demands and advancements in medical technologies. With a rising population and improving health awareness, th
Similar Deals
Adicon Holdings Limited → Crown Bioscience Inc.
2026
ADICON Holdings Limited
invested in
Crown Bioscience
in 2025
in a Other deal
Disclosed details
Transaction Size: $204M
Enterprise Value: $204M